Please login to the form below

Not currently logged in


  • Keeping the patient voice alive through all stages of drug development

    Thursday, 6 July 2023 - 1:00 pm

    Putting the patient first has never been higher up the agenda throughout the drug development process, but can we further fine-tune our approach? Tune into this webinar where we ask: • How important is early patient engagement to business success. • How do you ensure the patient voice is as ‘loud’ in later stages • Whose responsibility is it to ensure the patient voice is heard Viewers will come out with a deeper understanding of how to best keep the patient voice alive through all stages of drug development.

    Mark Doyle, Founder, A Life in a Day Additional panelists TBC shortly

    FREE |

  • Navigating patients step by step on their clinical trial journey

    Wednesday, 24 May 2023 - 3:00 pm

    For clinical trial participants, navigating their way through a study can sometimes seem daunting and complicated. Without the right support, around 30% are likely to drop out [1], resulting in extra financial costs for sponsors and potentially placing the future of the trial in jeopardy.

    John Pinching, Kari Reilly, Kristin Faber and Adel Sepulveda

    FREE |

  • Improving the Clinical Trial Experience: Why, How, and What?

    Thursday, 9 March 2023 - 2:00 pm

    In this webinar Langland will speak to Jonathan Moshinsky, Co-Founder and CEO of Stitch, a technology start-up supporting participant retention by enabling in-study feedback, and Sofia Fionda, Co-Founder of Boxee Group, a healthcare specialist market research agency with expertise in uncovering what motivates people to take part in trials. Join us to explore the why, how and what of improving the clinical experience for participants, sites, and sponsors.

    Sofia Fionda, Jonathan Moshinksy and Harry Yeates


  • Patient Recruitment: Think Global, Act Local

    Wednesday, 22 February 2023 - 3:00 pm

    Global clinical trials are a vital component of pharma R&D. Utilizing sites in multiple countries not only provides increased access to eligible and diverse patients - and therefore more robust data - but also promotes health equity and research and innovation across continents.

    Georgia Harding, Nicole Yingst, Barbara OrlosKaminska


  • Breaking Internal Silos to Ensure Patient Centricity is a Key Focus Company-Wide

    Thursday, 6 October 2022 - 3:00 pm

    Mark and Urs will be discussing the pros and cons of an enterprise-wide approach to patient centricity, and explore the measurable benefits it could deliver. • Who should be involved in patient centric initiatives? • Should organisations focus their energies (and budget) on customer-facing or medical colleagues – or is there a benefit to including other functions?

    Urs Voegli, Managing Director, Janssen Switzerland & Mark Doyle, Founder, A Life in a Day


  • Overcoming Patient Recruitment Challenges in Rare Disease Trials

    Wednesday, 28 September 2022 - 3:00 pm

    Rare diseases are thought to affect up to 446 million people worldwide. With more than 7,000 rare diseases, most of which are genetic, it’s vital all patients can access new and effective treatments.

    Whitney Taynton, Margaret Alege


  • Agreeing sustainable value-based contracts with payers: myths and realities

    Wednesday, 13 July 2022 - 10:30 am

    Value-based contracts (VBC) are increasingly considered by companies for many types of therapies. Some companies are suggesting that VBC will become the default for them across their portfolio.

    Josie Godfrey, Malcom Qualie, Heather McDonald, John Pincher


  • Diversity in Pharma: The Impact of COVID-19 on DE&I

    Thursday, 23 June 2022 - 3:00 pm

    COVID-19 has had a huge impact on how we all think and act. Our working environments may look very different now to the way they did pre-pandemic, and not all the changes have been negative.

    Andrés López Castaño, Tricia Lucas-Clarke, Noor Shaker, Sandra Van de Cauter, Marsha N. Ganthier


  • Accelerating patient recruitment in clinical trials post COVID-19

    Wednesday, 8 June 2022 - 3:00 pm

    Patient recruitment is arguably one of the most important aspects of a clinical trial. Without enough participants, trials will inevitably fail, meaning potentially effective therapies will not be brought to market.

    Kate Shaw, Founder & CEO, Innovative Trials; Jane Thurston, Senior Patient Recruitment Lead, Parexel; Whitney Taynton, Business Unit Head, Innovative Trials


  • Smarter Strategies Webinar Smarter strategies: precise customer-centric digital engagement with the NHS

    Thursday, 31 March 2022 - 3:00 pm

    Having traditionally found itself near the bottom of digital adoption league tables, the scale and maturity of customer engagement practices within the pharmaceutical industry, accelerated by the COVID-19 pandemic, are now building at considerable pace.

    Simon Grime: Digital Engagement Director, Wilmington Healthcare Tina White: Principal Clinical Consultant – Commissioning, Wilmington Healthcare Julian Snape: Commercial Optimisation Director, Wilmington Healthcare


  • Diversity in Clinical Trials : A more inclusive approach in patient recruitment

    Thursday, 24 February 2022 - 2:00 pm

    We have seen a growing focus on patient diversity in clinical trials in recent years, but the COVID-19 vaccine trials in particular have highlighted the importance of achieving diverse patient recruitment.

    Kate Shaw - Founder/CEO, Innovative Trials


  • After the wildfire: how will healthcare recover from the pandemic?

    Thursday, 20 January 2022 - 2:00 pm

    Following a forest fire, the natural world recovers according to predictable patterns, in a process known as ‘ecological succession’. After the global conflagration of COVID-19, what will the equivalent patterns look like for health?

    Langland, a Publicis Health Company


  • Beyond the Blame Game: Improving Patient, Physician, Pharma Relations

    Wednesday, 7 November 2018 - 3:00 pm

    We often hear patients report a lack of ‘connection’ with their physician, and where lifestyle plays a role in the development of a disease, such as obesity or type 2 diabetes, patients may even feel the doctor blames them for their condition.

    Andrew McConaghie, Group Editor


  • Transforming Access to Medicines Through Patient-Centric Solutions

    Thursday, 14 December 2017 - 2:00 pm

    As medicines access evolves and pharmaceutical companies take an increasingly nuanced approach to it, it’s ever-more important to focus on particular aspects of this area and investigate whether firms are operating optimally.

    Dominic Tyer, Editorial director


  • The Future of Marketing in Life Sciences: Is your function fit for purpose

    Thursday, 30 November 2017 - 2:00 pm

    The healthcare landscape is rapidly changing as it responds to a multitude of well-known issues. Coupled with emerging digital technologies, these drivers are shaping the industry, moving it towards a more sophisticated, outcomes-driven model that demands a new approach.

    Dominic Tyer, Editorial director


  • The Power of Storytelling in Health: Friend or Foe?

    Wednesday, 15 November 2017 - 3:00 pm

    With traditional media moving online, and the era of social media driving stories through the ethernet, never has a ‘story’ been more impactful.

    Dominic Tyer, Editorial director


  • The Truth about Doctors

    Thursday, 19 October 2017 - 3:00 pm

    ‘The Truth about Doctors’ the first study in the series, aims to get to the heart of the human under the white coat to better understand what motivates doctors and how we can improve the way we communicate to them.

    Dominic Tyer, Editorial director


  • Proving the Strategic Value of Patients

    Tuesday, 10 October 2017 - 3:00 pm

    Patient insights aren’t just a ‘nice to have’: they are essential to understand the space where Pharma’s drugs ‘live’.

    Dominic Tyer, Editorial director


  • Regret Minimisation

    Tuesday, 11 July 2017 - 3:00 pm

    When new products approach the market the level of demand for them is often exaggerated.

    Dominic Tyer, Editorial director


  • Assessing early market opportunity

    Wednesday, 19 April 2017 - 3:00 pm

    To successfully develop and launch an asset it’s crucial to identify and define the commercial value early in the process.

    Dominic Tyer, Editorial director


Previous 1 2 3 4 Next

Subscribe to our email news alerts


Add my company
Page & Page and Partners

Page & Page is an independent creative agency on a mission to close the healthcare gap through the power of...

Latest intelligence

Actinic keratosis – a common skin condition that can lead to skin cancer
PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
Man vs microbe: the fight against antimicrobial resistance
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...